Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
Photo by Sangharsh Lohakare / Unsplash
Key Takeaway
Recognize immune and stromal programs correlate with survival in early-stage lung adenocarcinoma without causality.
This retrospective cohort study evaluated gene expression programs in early-stage (IA/IB) lung adenocarcinoma patients from multiple sources. The analysis utilized data from 292 patients in NCBI GEO datasets and 90 patients in TCGA-LUAD. The study design was observational, meaning associations do not imply causation. Follow-up duration was not reported in the available data.
The exposure consisted of gene expression programs categorized as immune, stromal, or tumor-intrinsic. No specific comparator group was reported for these molecular profiles. The investigation focused on how these molecular signatures correlated with clinical outcomes in the specified population of patients.
Regarding recurrence, modules enriched for B-cell and antibody responses, vascular homeostasis, and regulation of fibrotic remodeling were associated with reduced recurrence. Conversely, modules enriched for epithelial organization and extracellular matrix remodeling conferred increased risk. For overall survival, immune-related programs were associated with improved survival. However, extracellular matrix and epithelial differentiation or proliferation programs were associated with worse survival. Effect sizes, absolute numbers, and p-values were not reported. No confidence intervals were available to assess the precision of these associations.
Safety data, including adverse events and discontinuations, were not reported. The study did not list specific limitations or funding sources. Practice relevance was not reported. Clinicians should recognize these findings as hypothesis-generating due to the observational nature and lack of statistical metrics. Uncertainty remains regarding the clinical utility of these gene expression programs for current practice.
More on Lung Adenocarcinoma
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
A Rare Tumor That Fooled Doctors at Every Step — Until One Test Changed Everything
This case report and literature review describes a 64-year-old male with thoracic SMARCA4-deficient undifferentiated tumor initially misdiag…
A rare chest tumor mimicking lung cancer was misdiagnosed until a specific genetic test revealed the true cause, proving one marker can prev…
Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
AI Now Reads Tumor Slides Like a Radiologist — and Shows Its Work
This review/commentary outlines a Virtual Spectral Decomposition (VSD) methodological framework for analyzing digital pathology and imaging …
A new AI system reads cancer slides like a doctor and explains exactly which biological features drove each diagnosis.
NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models.
A Hidden Cell Type in Lung Cancer May Hold a New Target
This preclinical and computational study analyzed public databases and performed in vitro experiments to evaluate cancer-associated fibrobla…
A hidden protein in support cells around lung tumors may drive cancer growth, pointing to a new treatment target for lung adenocarcinoma.
View Original Abstract ↓
BackgroundEarly-stage lung adenocarcinoma (LUAD) patients with similar pathological stage exhibit heterogeneous recurrence risk. Prior work suggested that intra-tumoral immune composition, particularly B cells, regulatory T cells, and macrophages stratify recurrence outcomes. These immune programs operate in the context of stromal and tumor-intrinsic transcriptomic programs.ObjectiveTo identify coordinated gene expression programs linking immune, stromal and tumor-intrinsic processes to recurrence in early-stage (IA/IB) LUAD, and to assess their prognostic relevance in an independent cohort using overall survival.MethodsGene expression data of 292 patients in NCBI GEO datasets was reanalyzed and unsupervised clusters were identified within the differentially expressed genes (DEGs) that associated with recurrence. Protective and risk-associated genes were identified in covariate-adjusted Cox models. GO enrichment was performed using DEGs. Pathway-level principal component scores were tested for association with overall survival in TCGA-LUAD early-stage, treatment-naive patients (n=90).ResultsModules enriched for B-cell and antibody responses, vascular homeostasis, and regulation of fibrotic remodeling were associated with reduced recurrence, whereas those enriched for epithelial organization and extracellular matrix (ECM) remodeling conferred increased risk. The contrast between ECM-driven recurrence risk and protective immune programs may reflect distinct biological states associated with recurrence timing, wherein changes in the ECM precede impaired lymphocyte responses in early-stage disease. In the TCGA cohort, immune-related programs associated with improved survival, whereas extracellular matrix (ECM) and epithelial differentiation/proliferation programs associated with worse survival.SignificanceThis study integrates immune, tumor, and stromal transcriptional programs to identify a prognostic dichotomy between ECM remodeling and adaptive immune-supportive states in early-stage LUAD. These coordinated tumor states and immune-matrix interactions offer mechanistic insight into recurrence and provide a framework for risk stratification.
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma.
New Asthma Drug Cuts Attacks Without Recent Crisis
Related in Allergy & Immunology
Emergency-use spacers improve salbutamol delivery in asthmatics compared to pMDI alone
Spacers boost asthma drug delivery over inhaler alone
This randomized trial in 108 asthmatics compared emergency-use spacers with pMDI alone. Spacers significantly increased urinary salbutamol a…
Using a spacer with your asthma inhaler delivers more medication to the lungs, a new trial finds. Some spacers work better than others.
Repeated counseling with pMDI devices reduced inhalation errors in adult asthma patients compared to pMDI alone.
Spacer Devices Fix Asthma Faster Than Inhalers Alone
This prospective randomized clinical trial enrolled 300 adult asthma patients to compare repeated counseling on inhalation technique using p…
Using a spacer with an inhaler reduces mistakes and improves lung health much faster than using the inhaler alone for adults with asthma
Montelukast vs Tiotropium Added to ICS in Children With Asthma
Asthma Treatment Comparison Shows Mixed Results for Kids
This randomized controlled trial in 152 children aged 6 to 14 years with partly controlled or uncontrolled asthma found no significant diffe…
A small trial found no clear difference between two asthma medicines for children, though one caused rare side effects.
Nurse-led rehabilitation consultation improves asthma control in primary care
A Simple 4-Week Plan Helps Asthma Control
This randomized controlled trial in 124 adults with asthma found that a nurse-led structured rehabilitation consultation significantly impro…
A simple four-week nurse program helps adults manage asthma better than usual care alone.
From Other Specialties
Therapeutic Touch Reduces Crying and Improves Sleep in Infants With Colic
Therapeutic touch reduces crying in babies with colic
This randomized controlled trial in 96 infants with colic found that therapeutic touch based on Watson's Human Care Theory significantly red…
A new trial shows gentle therapeutic touch helps babies cry less and sleep better when they have infantile colic.
Mycophenolate mofetil non-inferior to prednisone for first-episode nephrotic syndrome in children
Mycophenolate Mofetil Offers Alternative to Steroids for Nephrotic Syndrome
This phase 3 non-inferiority trial randomized 272 children aged 1-10 years with first-episode steroid-sensitive nephrotic syndrome to mycoph…
A new trial shows mycophenolate mofetil works as well as prednisone for children with nephrotic syndrome, with fewer steroid side effects.
AquOTic water competency intervention improves outcomes in children with autism
Water therapy improves skills for children with autism spectrum disorder
This pre-post cohort study of 37 children with autism ages 5 to 9 found that a 10-week occupational therapy-based water competency intervent…
A water-based occupational therapy program significantly improved performance and satisfaction scores in children with autism spectrum disor…
Play-based cognitive flexibility training boosts creativity in third graders
Playful workshops boost story skills and flexible thinking for third graders
This RCT in 249 third graders found that a 14-session play-based workshop significantly improved narrative creativity and cognitive flexibil…
A fun 14-session workshop helped third graders write better stories and think more flexibly than peers in regular classes.